NCT07574541 2026-05-27Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active SurveillanceNational Institutes of Health Clinical Center (CC)Phase 2 Not yet recruiting52 enrolled